Proyectos de Investigación
Project ECAEC235235DELG
First-in-human, open-label, prospective, non-randomized clinical trial to evaluate the safety of ARI-HER2 (HER2BBz CAR-T cells) in subjects with relapse or refractory HER2-positive metastatic breast cancer.
edit_calendar
Duration: from 01 December 2023 to 30 November 2028
(60 months)
Current
euro
22,000.00 EUR
Of National scope.
Researchers
Marta
Santisteban Eslava
Leader